Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Maybe Parnate again?

Posted by JaclinHyde on March 31, 2006, at 14:39:02

In reply to Maybe Parnate again?, posted by Whit_in_Texas on March 31, 2006, at 6:40:48

Ok taking all of the meds in account plus parnate this is what Medscape says (it is loooong)

Patient Regimen

CLOMIPRAMINE ORAL
LAMICTAL ORAL
REMERON ORAL
PARNATE ORAL
WELLBUTRIN ORAL

Interactions

Contraindicated Drug Combination
TRI;TETRACYCLIC COMPOUNDS/MAOIS
Clomipramine Oral and Parnate Oral may interact based on the potential interaction between TRI;TETRACYCLIC COMPOUNDS and MAOIS.
TRI;TETRACYCLIC COMPOUNDS/MAOIS
Remeron Oral and Parnate Oral may interact based on the potential interaction between TRI;TETRACYCLIC COMPOUNDS and MAOIS.
BUPROPION/MAOI'S
Wellbutrin Oral and Parnate Oral may interact based on the potential interaction between BUPROPION and MAOI'S.

Moderate Interaction
BUPROPION/ANTIDEPRESSANTS
Wellbutrin Oral and Clomipramine Oral may interact based on the potential interaction between BUPROPION and ANTIDEPRESSANTS.
BUPROPION/ANTIDEPRESSANTS
Wellbutrin Oral and Remeron Oral may interact based on the potential interaction between BUPROPION and ANTIDEPRESSANTS.

Tri; Tetracyclic Compounds/MAOI'S

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

MONOGRAPH TITLE: Tri; Tetracyclic Compounds/MAOI'S

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Two possible mechanisms have been proposed for this interaction. MAO inhibitors may enhance the effects of the tricyclic antidepressants indirectly through inhibition of microsomal enzymes. Tricyclic antidepressants may sensitize adrenergic receptors to amines which then accumulate extraneuronally as a result of MAO inhibition.

CLINICAL EFFECTS: Increased effects of both drugs. Severe reactions including hyperpyrexia, convulsions, excitability, muscular rigidity, fluctuations in blood pressure, convulsions, grand mal seizures, coma, and death have been reported.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The concurrent use of tricyclic antidepressants and MAO inhibitors is contraindicated by the manufacturers of tricyclic antidepressants and tranylcypromine.

The manufacturers of tricyclic antidepressants and mirtazapine recommend at least 14 days between switching therapies. The manufacturer of tranylcypromine recommends a medication-free interval of at least a week when initiating tranylcypromine in patients who have previously received a tricyclic antidepressant, then initiating tranylcypromine at a reduced dosage of 50% for one week.

The manufacturer of phenelzine states that if phenelzine is used concurrently with or within 10 days of another antidepressant, the patient should be cautioned regarding the possibility of an adverse drug interaction.

DISCUSSION: It should be noted that if this interaction occurs, the consequences will be immediate and severe. Effects may continue to be seen for several days after discontinuing the MAOI. Similarity between cyclobenzaprine and TCA's warrants consideration of TCA interactions for cyclobenzaprine. Mirtazapine, a tetracyclic antidepressant, should also be considered for this interaction. Furazolidone and linezolid are known to inhibit MAO.

REFERENCES:

1.Brachfeld J, Wirtshafter A, Wolfe S. Imipramine-tranylcypromine incompatibility. Near-fatal toxic reaction. JAMA 1963 Dec 28; 186(13):1172-3.

2.Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979 Nov 24;2(6201):1315-7.

3.Pentel P, Olson KR, Becker CE, Benowitz N. Late complications of tricyclic antidepressant overdose. West J Med 1983 Mar;138(3):423-4.

4.de la Fuente JR, Berlanga C, Leon-Andrade C. Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports. J Clin Psychiatry 1986 Jan;47(1):40-1.

5.Pascual J, Combarros O, Berciano J. Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment Clin Neuropharmacol 1987 Dec;10(6):565-7.

6.Richards GA, Fritz VU, Pincus P, Reyneke J. Unusual drug interactions between monoamine oxidase inhibitors and tricyclic antidepressants. J Neurol Neurosurg Psychiatry 1987 Sep;50(9):1240-1.

7.Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 1987 Jul;42(7):760-3.

8.O'Brien S, McKeon P, O'Regan M, O'Flaherty A, Patel R. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992 Apr;12(2):104-9.

9.Schuckit M, Robins E, Feighner J. Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry 1971 Jun;24(6):509-14.

10.Graham PM, Potter JM, Paterson J. Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction. Lancet 1982 Aug 21; 2(8295):440.

11.White K, Simpson G. The combined use of MAOIs and tricyclics. J Clin Psychiatry 1984 Jul;45(7 Pt 2):67-9.

12.Ponto LB, Perry PJ, Liskow BI, Seaba HH. Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 1977 Sep;34(9):954-61.

13.Manshadi MS, Lippmann SB. Combined treatment of refractory depression with an MAO inhibitor and a tricyclic. Psychosomatics 1984 Dec; 25(12):929-31.

14.Spigset O, Mjorndal T, Lovheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993 Jan 23;306(6872):248.

15.Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993 Dec 4;342(8884):1419.

16.Sjoqvist F. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med 1965 Nov;58(11 Part 2):967-78.

17.Stern SL, Mendels J. Drug combinations in the treatment of refractory depression: a review. J Clin Psychiatry 1981 Oct;42(10):368-73.

18.White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1981 Sep;1(5):264-82.

19.Nardil (phenelzine sulfate) US prescribing information. Parke-Davis January, 2005.

20.Elavil (amitriptyline hydrochloride) US prescribing information. AstraZeneca February, 2003.

21.Remeron (mirtazapine) US prescribing information. Organon Inc. January, 2005.

22.Pamelor (nortriptyline hydrochloride) US prescribing information. Mallinckrodt February 4, 2005.

23.Anafranil (clompiramine hydrochloride) US prescribing information. Mallinckrodt February 3, 2005.

24.Parnate (tranylcypromine sulfate) US prescribing information. GlaxoSmtihKline January, 2005.


Bupropion/MAOI's

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

MONOGRAPH TITLE: Bupropion/MAOI's

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Unknown.

CLINICAL EFFECTS: The concurrent administration of bupropion and MAOI's may result in an increase in the acute toxicity of bupropion.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of bupropion states that concurrent administration of bupropion and a MAO inhibitor is contraindicated. The manufacturer recommends that 14 days should elapse between the discontinuation of a MAO inhibitor and the initiation of bupropion.(1)

DISCUSSION: There is no clinical documentation to support this interaction. The manufacturer of bupropion states that concurrent administration of bupropion and a MAO inhibitor is contraindicated. The manufacturer also states that 14 days should elapse between the discontinuation of a MAO inhibitor and the initiation of bupropion.(1)

REFERENCES:

1.Wellbutrin (bupropion hydrochloride) US prescribing information. GlaxoSmithKline January, 2005.


Bupropion/Antidepressants

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

MONOGRAPH TITLE: Bupropion/Antidepressants

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Both bupropion and antidepressants are known to lower the seizure threshold.(1)

CLINICAL EFFECTS: Concurrent use of bupropion and an antidepressant may result in additive effects on the seizure threshold, increasing the risk of seizures.(1)

PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants an anorectics; a total daily dose of bupropion greater than 450 mg or single doses greater than 150 mg; rapid escalation of bupropion dosage; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). (1)

PATIENT MANAGEMENT: The concurrent use of bupropion and antidepressants should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1)

DISCUSSION: Because of the risk of seizure from concurrent bupropion and other agents that lower seizure threshold, the manufacturer of bupropion states that the concurrent use of bupropion and antidepressants should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1)

REFERENCE:

1.Wellbutrin (bupropion hydrochloride) US prescribing information. GlaxoSmithKline January, 200"

JH


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:JaclinHyde thread:626994
URL: http://www.dr-bob.org/babble/20060329/msgs/627142.html